FCGR2B and breast cancer: In contrast, no significant evidence of CD32 down-regulation is detectable upon conjugation with hematopoietic cells, a variety of epithelial cancer cells, two normal, primary fibroblasts, and one myoblast cell line, indicating that CD32 ligand(s) is preferentially expressed on BC cells.